Paratek Pharmaceuticals
Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
OptiNose
Acquisition in 2025
OptiNose is a specialty pharmaceutical company focused on nasal drug delivery technologies and therapies for ear, nose, and throat conditions and related allergies. Its Exhalation Delivery System enables topically acting corticosteroids to reach the upper nasal cavity, supporting the commercial product XHANCE for chronic rhinosinusitis with and without nasal polyps. The company is advancing OPN-300 for Prader-Willi syndrome and autism spectrum disorder. It has licensing agreements for Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults and collaborates with Inexia Limited to develop orexin receptor targeting medicines. Founded in 2010 and based in Yardley, Pennsylvania, OptiNose aims to broaden nasal delivery with reproducible dosing and reduced systemic exposure.
Transcept Pharmaceuticals
Acquisition in 2014
Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.